Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

CD200R deletion promotes a neutrophil niche for Francisella tularensis and increases infectious burden and mortality.

Casulli J, Fife ME, Houston SA, Rossi S, Dow J, Williamson ED, Clark GC, Hussell T, D'Elia RV, Travis MA.

Nat Commun. 2019 May 9;10(1):2121. doi: 10.1038/s41467-019-10156-6.

2.

Friends or Foes? Emerging Impacts of Biological Toxins.

Clark GC, Casewell NR, Elliott CT, Harvey AL, Jamieson AG, Strong PN, Turner AD.

Trends Biochem Sci. 2019 Apr;44(4):365-379. doi: 10.1016/j.tibs.2018.12.004. Epub 2019 Jan 14. Review.

3.

Production, Characterisation and Testing of an Ovine Antitoxin against Ricin; Efficacy, Potency and Mechanisms of Action.

Whitfield SJC, Griffiths GD, Jenner DC, Gwyther RJ, Stahl FM, Cork LJ, Holley JL, Green AC, Clark GC.

Toxins (Basel). 2017 Oct 18;9(10). pii: E329. doi: 10.3390/toxins9100329.

4.

Mitogen-activated protein kinases (MAPKs) are modulated during in vitro and in vivo infection with the intracellular bacterium Burkholderia pseudomallei.

D'Elia RV, Saint RJ, Newstead SL, Clark GC, Atkins HS.

Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2147-2154. doi: 10.1007/s10096-017-3038-0. Epub 2017 Aug 30.

5.

Current and future developments in the treatment of virus-induced hypercytokinemia.

Wong JP, Viswanathan S, Wang M, Sun LQ, Clark GC, D'Elia RV.

Future Med Chem. 2017 Feb;9(2):169-178. doi: 10.4155/fmc-2016-0181. Epub 2017 Jan 27. Review.

PMID:
28128003
6.
7.

Modulation of Human Airway Barrier Functions during Burkholderia thailandensis and Francisella tularensis Infection Running Title: Airway Barrier Functions during Bacterial Infections.

Blume C, David J, Bell RE, Laver JR, Read RC, Clark GC, Davies DE, Swindle EJ.

Pathogens. 2016 Aug 3;5(3). pii: E53. doi: 10.3390/pathogens5030053.

8.

miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis.

Seashols-Williams SJ, Budd W, Clark GC, Wu Q, Daniel R, Dragoescu E, Zehner ZE.

PLoS One. 2016 Jul 22;11(7):e0159601. doi: 10.1371/journal.pone.0159601. eCollection 2016.

9.

Mechanisms of Disease: Host-Pathogen Interactions between Burkholderia Species and Lung Epithelial Cells.

David J, Bell RE, Clark GC.

Front Cell Infect Microbiol. 2015 Nov 18;5:80. doi: 10.3389/fcimb.2015.00080. eCollection 2015. Review.

10.

Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis.

Budd WT, Seashols-Williams SJ, Clark GC, Weaver D, Calvert V, Petricoin E, Dragoescu EA, O'Hanlon K, Zehner ZE.

PLoS One. 2015 Nov 6;10(11):e0142373. doi: 10.1371/journal.pone.0142373. eCollection 2015.

11.

Immune profiling of the progression of a BALB/c mouse aerosol infection by Burkholderia pseudomallei and the therapeutic implications of targeting HMGB1.

Laws TR, Clark GC, D'Elia RV.

Int J Infect Dis. 2015 Nov;40:1-8. doi: 10.1016/j.ijid.2015.09.003. Epub 2015 Sep 7.

12.

"FoxP3 Hunting" during infection with Francisella tularensis.

D'Elia RV, Laws TR, Núñez A, Clark GC.

Int J Immunopathol Pharmacol. 2014 Oct-Dec;27(4):585-95. doi: 10.1177/039463201402700414.

PMID:
25572738
13.

Delayed presence of alternatively activated macrophages during a Francisella tularensis infection.

D'Elia RV, Laws TR, Núñez A, Taylor C, Clark GC.

Microb Pathog. 2015 Jan;78:37-42. doi: 10.1016/j.micpath.2014.10.002. Epub 2014 Oct 2.

PMID:
25284816
14.

Targeting the "Rising DAMP" during a Francisella tularensis Infection.

D'Elia RV, Laws TR, Carter A, Lukaszewski R, Clark GC.

Antimicrob Agents Chemother. 2013 Sep;57(9):4222-4228. doi: 10.1128/AAC.01885-12. Epub 2013 Jun 24.

15.

Scaling of Haversian canal surface area to secondary osteon bone volume in ribs and limb bones.

Skedros JG, Knight AN, Clark GC, Crowder CM, Dominguez VM, Qiu S, Mulhern DM, Donahue SW, Busse B, Hulsey BI, Zedda M, Sorenson SM.

Am J Phys Anthropol. 2013 Jun;151(2):230-44. doi: 10.1002/ajpa.22270. Epub 2013 Apr 30.

PMID:
23633395
16.

Targeting the "cytokine storm" for therapeutic benefit.

D'Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC.

Clin Vaccine Immunol. 2013 Mar;20(3):319-27. doi: 10.1128/CVI.00636-12. Epub 2013 Jan 2. Review.

17.

Reactive oxygen species and the MEK/ERK pathway are involved in the toxicity of clostridium perfringens α-toxin, a prototype bacterial phospholipase C.

Monturiol-Gross L, Flores-Díaz M, Araya-Castillo C, Pineda-Padilla MJ, Clark GC, Titball RW, Alape-Girón A.

J Infect Dis. 2012 Oct;206(8):1218-26. Epub 2012 Aug 16.

PMID:
22904339
18.

Pegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery.

Morris CJ, Beck K, Fox MA, Ulaeto D, Clark GC, Gumbleton M.

Antimicrob Agents Chemother. 2012 Jun;56(6):3298-308. doi: 10.1128/AAC.06335-11. Epub 2012 Mar 19.

19.

Subtype analysis of Blastocystis isolates in Swedish patients.

Forsell J, Granlund M, Stensvold CR, Clark CG, Evengård B.

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1689-96. doi: 10.1007/s10096-011-1416-6. Epub 2012 Feb 15. Erratum in: Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1697. Clark, G C [corrected to Clark, C G].

20.

Analysis of the effect of osteon diameter on the potential relationship of osteocyte lacuna density and osteon wall thickness.

Skedros JG, Clark GC, Sorenson SM, Taylor KW, Qiu S.

Anat Rec (Hoboken). 2011 Sep;294(9):1472-85. doi: 10.1002/ar.21452. Epub 2011 Aug 1.

21.

Comparison of a nontoxic variant of Clostridium perfringens α-toxin with the toxic wild-type strain.

Vachieri SG, Clark GC, Alape-Girón A, Flores-Díaz M, Justin N, Naylor CE, Titball RW, Basak AK.

Acta Crystallogr D Biol Crystallogr. 2010 Oct;66(Pt 10):1067-74. doi: 10.1107/S090744491003369X. Epub 2010 Sep 18.

PMID:
20944240
22.

Ophthalmic presentation of Wegener's granulomatosis on a background of polymyalgia rheumatica.

Clark GC, Moloney G, Sutton G.

Clin Exp Ophthalmol. 2010 Jan;38(1):65-7. doi: 10.1111/j.1442-9071.2009.02217.x.

PMID:
20447103
23.

Novel peptide therapeutics for treatment of infections.

Oyston PC, Fox MA, Richards SJ, Clark GC.

J Med Microbiol. 2009 Aug;58(Pt 8):977-87. doi: 10.1099/jmm.0.011122-0. Epub 2009 Jun 15. Review.

PMID:
19528155
24.

Determination of relative assay response factors for toxic chlorinated and brominated dioxins/furans using an enzyme immunoassay (EIA) and a chemically-activated luciferase gene expression cell bioassay (CALUX).

Samara F, Gullett BK, Harrison RO, Chu A, Clark GC.

Environ Int. 2009 Apr;35(3):588-93. doi: 10.1016/j.envint.2008.11.003. Epub 2009 Jan 3.

PMID:
19121869
25.

Recombinant cell bioassay systems for the detection and relative quantitation of halogenated dioxins and related chemicals.

Denison MS, Zhao B, Baston DS, Clark GC, Murata H, Han D.

Talanta. 2004 Aug 8;63(5):1123-33. doi: 10.1016/j.talanta.2004.05.032.

PMID:
18969542
26.

Recombinant Bacillus subtilis expressing the Clostridium perfringens alpha toxoid is a candidate orally delivered vaccine against necrotic enteritis.

Hoang TH, Hong HA, Clark GC, Titball RW, Cutting SM.

Infect Immun. 2008 Nov;76(11):5257-65. doi: 10.1128/IAI.00686-08. Epub 2008 Sep 8.

27.

AH receptor agonist activity in human blood measured with a cell-based bioassay: evidence for naturally occurring AH receptor ligands in vivo.

Connor KT, Harris MA, Edwards MR, Budinsky RA, Clark GC, Chu AC, Finley BL, Rowlands JC.

J Expo Sci Environ Epidemiol. 2008 Jul;18(4):369-80. Epub 2007 Oct 3.

PMID:
17912254
28.

Mathematical model developed for environmental samples: prediction of GC/MS dioxin TEQ from XDS-CALUX bioassay data.

Brown DJ, Orelien J, Gordon JD, Chu AC, Chu MD, Nakamura M, Handa H, Kayama F, Denison MS, Clark GC.

Environ Sci Technol. 2007 Jun 15;41(12):4354-60.

29.

Analysis of protection afforded by a Clostridium perfringens alpha-toxoid against heterologous clostridial phospholipases C.

Neeson BN, Clark GC, Atkins HS, Lingard B, Titball RW.

Microb Pathog. 2007 Oct;43(4):161-5. Epub 2007 May 18.

PMID:
17604945
30.

Effects of Clostridium perfringens phospholipase C in mammalian cells.

Flores-Díaz M, Thelestam M, Clark GC, Titball RW, Alape-Girón A.

Anaerobe. 2004 Apr;10(2):115-23.

PMID:
16701508
31.

Dioxin concentration in human milk in Hebei province in China and Tokyo, Japan: potential dietary risk factors and determination of possible sources.

Sun SJ, Zhao JH, Liu HJ, Liu DW, Ma YX, Li L, Horiguchi H, Uno H, Iida T, Koga M, Kiyonari Y, Nakamura M, Sasaki S, Fukatu H, Clark GC, Kayama F.

Chemosphere. 2006 Mar;62(11):1879-88. Epub 2005 Sep 6.

PMID:
16140358
32.

Persistent organic pollutants in human milk in women from urban and rural areas in northern China.

Sun SJ, Zhao JH, Koga M, Ma YX, Liu DW, Nakamura M, Liu HJ, Horiguchi H, Clark GC, Kayama F.

Environ Res. 2005 Nov;99(3):285-93. Epub 2005 Jul 21.

PMID:
16039646
33.

Analysis of Ah receptor pathway activation by brominated flame retardants.

Brown DJ, Van Overmeire I, Goeyens L, Denison MS, De Vito MJ, Clark GC.

Chemosphere. 2004 Jun;55(11):1509-18.

PMID:
15099731
34.

Clostridium absonum alpha-toxin: new insights into clostridial phospholipase C substrate binding and specificity.

Clark GC, Briggs DC, Karasawa T, Wang X, Cole AR, Maegawa T, Jayasekera PN, Naylor CE, Miller J, Moss DS, Nakamura S, Basak AK, Titball RW.

J Mol Biol. 2003 Oct 31;333(4):759-69.

PMID:
14568535
35.

Evidence of aryl hydrocarbon receptor ligands in Presque Isle Bay of Lake Erie.

Gray JP, Leas TL, Obert E, Brown D, Clark GC, Vanden Heuvel JP.

Aquat Toxicol. 2003 Aug 20;64(3):343-58.

PMID:
12842597
36.

Validation of the CALUX bioassay for the screening of PCDD/Fs and dioxin-like PCBs in retail fish.

Tsutsumi T, Amakura Y, Nakamura M, Brown DJ, Clark GC, Sasaki K, Toyoda M, Maitani T.

Analyst. 2003 May;128(5):486-92.

PMID:
12790202
37.

Application of high-density array-based signature-tagged mutagenesis to discover novel Yersinia virulence-associated genes.

Karlyshev AV, Oyston PC, Williams K, Clark GC, Titball RW, Winzeler EA, Wren BW.

Infect Immun. 2001 Dec;69(12):7810-9.

38.

Increased tumor necrosis factor-alpha production by peripheral blood leukocytes from TCDD-exposed rhesus monkeys.

Rier SE, Coe CL, Lemieux AM, Martin DC, Morris R, Lucier GW, Clark GC.

Toxicol Sci. 2001 Apr;60(2):327-37.

PMID:
11248145
39.
40.

A new cytochrome P450 (CYP30) family identified in the clam, Mercenaria mercenaria.

Brown DJ, Clark GC, Van Beneden RJ.

Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):351-60.

PMID:
9972477
41.

Effects of TCDD on Ah receptor, ARNT, EGF, and TGF-alpha expression in embryonic mouse urinary tract.

Bryant PL, Clark GC, Probst MR, Abbott BD.

Teratology. 1997 May;55(5):326-37.

PMID:
9261927
42.
43.

Isolation and characterization of a novel gene induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver.

Selmin O, Lucier GW, Clark GC, Tritscher AM, Vanden Heuvel JP, Gastel JA, Walker NJ, Sutter TR, Bell DA.

Carcinogenesis. 1996 Dec;17(12):2609-15.

PMID:
9006096
44.

Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus.

Richards RG, DiAugustine RP, Petrusz P, Clark GC, Sebastian J.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):12002-7.

45.

Differences in binding of epidermal growth factor to liver membranes of TCDD-resistant and TCDD-sensitive rats after a single dose of TCDD.

Tuomisto J, Sewall CH, Unkila M, Pohjanvirta R, Clark GC, Viluksela M, Rozman K, Lucier GW.

Environ Toxicol Pharmacol. 1996 Apr 15;1(2):109-16.

PMID:
21781670
46.

Induced gene transcription: implications for biomarkers.

Sewall CH, Bell DA, Clark GC, Tritscher AM, Tully DB, Vanden Heuvel J, Lucier GW.

Clin Chem. 1995 Dec;41(12 Pt 2):1829-34. Review.

47.
48.

Rat CYP1B1: an adrenal cytochrome P450 that exhibits sex-dependent expression in livers and kidneys of TCDD-treated animals.

Walker NJ, Gastel JA, Costa LT, Clark GC, Lucier GW, Sutter TR.

Carcinogenesis. 1995 Jun;16(6):1319-27.

PMID:
7788849
49.

TCDD reduces rat hepatic epidermal growth factor receptor: comparison of binding, immunodetection, and autophosphorylation.

Sewall CH, Clark GC, Lucier GW.

Toxicol Appl Pharmacol. 1995 Jun;132(2):263-72.

PMID:
7785053
50.

Alterations in thyroid function in female Sprague-Dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Sewall CH, Flagler N, Vanden Heuvel JP, Clark GC, Tritscher AM, Maronpot RM, Lucier GW.

Toxicol Appl Pharmacol. 1995 Jun;132(2):237-44.

PMID:
7540335

Supplemental Content

Loading ...
Support Center